Objectives: Characterization of an in vitro diagnostic zinc assay (LT-SYS) on a Roche cobas c502 analyzer and evaluation of the influence of pre-analytic factors on zinc concentration measurements.
| INTRODUCTION
Among the trace elements of the human body zinc is the second most abundant (after iron), with a total estimated zinc body content of 2-3 g.
1
Zinc is an essential component of more than 300 enzymes and of an even greater number of proteins, in fact at least 10% of the human genome (approx. 2800 gene products) are predicted to encode zinc proteins. 2 Given its near ubiquitous presence in the human body, zinc plays a key role in many catalytic, structural, and regulatory processes.
3
While acute and chronic intoxication with zinc is rather rare, 4 zinc deficiency is much more common and can cause serious immunological as well as growth and developmental impairments, depending on the severity of zinc deficiency and age group. [5] [6] [7] The main cause of zinc deficiency in humans is a low zinc diet or diet with high phytate content, both conditions more frequently encountered in developing countries. In contrast, inherited zinc deficiency, Acrodermitis enteropathica (AE), is a rare gene defect with an estimated incidence of 1 in 500 000. 5 Unless treated with zinc supplementation, AE leads to periorificial and acral dermatitis, alopecia and diarrhea and can ultimately be fatal. 8 Zinc status in patient with suspected zinc deficiency can be assessed from several biological materials with the most common being plasma/serum blood samples or urine samples. 9 However, plasma/serum zinc status is not only influenced by zinc deficiency, also inflammation can lower plasma zinc levels 10 and as such interpretation of plasma zinc levels is not always straightforward.
11,12
Methods for the analysis of plasma or serum zinc concentrations range from atomic absorption spectrophotometry over mass spectrometry to the more commonly used photometry. [13] [14] [15] Photometric methods can be with or without deproteinization, with both approaches using the binding of zinc to a chromogenic component. 15 What all methods of zinc measurement have in common is, that they are prone to influences from preanalytic factors like time elapsed between blood collecting and analysis or zinc contaminations during the process of blood collecting. [16] [17] [18] [19] [20] [21] [22] In this study, we describe the validation of the LT-SYS colometric zinc in vitro diagnostic assay on a Roche cobas c502 analyzer, which is part of a Roche cobas 8000 automated modular platform in the University Clinic Halle (UKH). To date Roche has no zinc assay in its analytic portfolio, rendering it necessary to use third party zinc assays, which are often provided by small to medium scale companies.
The validation and characterization of this zinc assay and a method comparison to a previously used assay were based on several CLSI protocols, with the details given below in the material and methods section. Additionally to the characterization of the zinc assay, we also evaluated the potential influence of preanalytic factors on zinc measurements, namely time elapsed until analysis both before and after centrifugation, the usage of different types of samples tubes and their mode of transportation to the laboratory.
| MATERIALS AND METHODS
The LT-SYS quantitative in vitro zinc assay without deproteinization Hospital Halle is part of a fully automated Roche cobas 8000 platform with a cobas 8100 pre-analytic unit and three cobas 8000 units. The
Roche cobas 8000 platform and all its components are operated according to the manufacturer's instructions and manuals, with routine maintenance and quality control procedures.
The Wako zinc assay (Wako chemicals GmbH, Neuss, Germany), which was used as comparative method in this study, is also a 5-Br-PAPS based method albeit with deproteinization of the sample with trichloroacetic acid. The resulting color complex is being measured at 560 nm wavelength with a light path of 1 cm. 
| Imprecision and bias
Imprecision and bias of the LT-SYS quantitative in vitro zinc assay were calculated based on the CLSI EP05-A3 guideline, using a 2×2×20 experimental design. 23 We used four different sample types for the precision experiment: two commercial control sera, one plasma and one urine based sample pool. The two commercial con- 
| Linearity
Linearity of the LT-SYS zinc assay was evaluated based on the NCCLS EP06-A guideline, 24 for a total of seven different concentration levels, covering the range from 34.7 μmol/L down to 1.15 μmol/L (226.9 to 7.51 μg/dL), with double measurements at each concentration (total n=14). We used the standard calibrator and saline solution (0.9% NaCl) to generate a suitable concentration series.
| Limit of blank (LoB) and limit of detection (LoD)
Limit of blank and LoD were estimated based on the CLSI EP17-A2 guideline using a total of 60 blank and 108 low concentration measurements. 25 As blank samples we used saline solution, which is also recommended by the test supplier for dilutions of patient samples at high concentrations. A total of five blank samples were measured over 3 days with four measurements each day. As low concentration samples we diluted nine patient lithium heparin plasma samples (obtained from routine zinc analysis) with saline solution (1:20 dilution) to obtain a zinc concentration close enough to the LoB to be meaningful for the determination of the LoD (<0.85 μmol/L or 5.56 μg/dL).
These nine diluted patient samples were analyzed on 3 days with four measurements each day. Before measurement of samples, the system was calibrated each day to introduce some additional source of variation.
| Method comparison
The LT-SYS zinc assay on the Roche cobas c502 Analyzer was compared to the previously used Wako zinc assay on a Roche cobas Mira Plus analyzer. Based on the CLSI EP09-A3 guideline, 26 a total of 60 lithium heparin plasma samples (residual de-identified specimens from routine zinc analysis) were measured on both analyzing systems.
| Serum-Plasma zinc concentration comparison
To gauge the differences between zinc concentrations obtained from serum or plasma samples, we collected a total of 60 plasma and serum sample pairs from residual de-identified patient specimen. These 60 serum/plasma sample pairs were subsequently analyzed with the LT-SYS zinc assay on the Roche cobas c502 Analyzer and compared with each other, again based on the CLSI EP09-A3 guideline. 
| Preanalytic aspects before centrifugation
In order to be able to quantify the impact of the time elapsed be- 
| Preanalytic aspects after centrifugation
In a second experimental approach we evaluated both the influence of time elapsed after centrifugation and the type of sample tube on zinc concentration measurements. Here, we took blood samples from 10 healthy volunteers, with the blood samples being collected in a serum tube (S-Monovette ® 4.9 mL Z-Gel), a plasma tube (S-Monovette 
| Statistical analysis
The imprecision of the LT-SYS zinc assay was calculated using an ANOVA. Bias was estimated as relative and absolute bias from the respective target value. Linearity was assessed by a polynomial regression analysis to first-, second-, and third-order polynomials. 
| RESULTS

| Imprecision and bias
The imprecision values obtained for the LT-SYS zinc assay were generally low and ranged from CV=0.6% to 2.4% for repeatability and from CV=0.9% to 5.0% for laboratory (total) imprecision depending
on the type of material tested. A detailed description of all obtained imprecision values for the tested materials is given in Table 1 .
The estimated bias for the serum based control material was low, with 
| Linearity
Over the analyzed measuring range (1.15-34.7 μmol/L or 7.51-226.9 μg/dL) no deviation from linearity could be observed and no 2nd/3rd order polynomial fit was statistically better than a linear fit at the 1% significance level (best linear fit: y=0.025+0.966x; r=.999).
| Limit of blank (LoB) and limit of detection (LoD)
Based on the 60 blank sample measurements, the estimated limit of blank was LoB=0.17 μmol/L (1.11 μg/dL). The mean value for the blank samples was 0.06 μmol/L (0.39 μg/dL) with a standard deviation of SD=0.07 μmol/L (0.46 μg/dL). The measurement of the nine diluted patient samples (total n=108) resulted in a mean of 0.30 μmol/L (2.00 μg/dL) and a pooled standard deviation of SD=0.34 μmol/L (2.22 μg/dL). The resulting limit of detection was then calculated as LoD=0.73 μmol/L (4.77 μg/dL).
| Method comparison
Based on the comparison of the 60 patient samples, the two zinc as- Figure 1 shows the Passing-Bablok regression and the relative Bland-Altman plot for the comparison of the two zinc assays.
| Serum-plasma zinc concentration comparison
The 
| Preanalytic aspects before centrifugation
| Preanalytic aspects after centrifugation
The 290 zinc measurements from three different types of blood collection tubes (Figure 4) 
| DISCUSSION
The validation and characterization of the LT-SYS in vitro diagnostic zinc assay, which was based on the respective CLSI guidelines, [23] [24] [25] [26] found the assay to be well suited for routine measurement of zinc concentrations in patient samples on the Roche cobas c502 analyzer.
All validation goals were met, with an overall good degree of imprecision, a low limit of blank and detection (LoB, LoD) and no deviation from linearity over the measuring range relevant for routine diagnostic purposes.
To cover all possible types of sample specimen, we used plasma, serum and urine based samples for the estimation of imprecision (Table 1) , thereby covering zinc concentrations from 8.7 μmol/L (56.6 μg/dL) to 33.1 μmol/L (216.3 μg/dL). The coefficient of variation (CV) was inversely proportional to the zinc concentration level, while the absolute imprecision seemed quite constant for the serum and plasma pools, only being markedly higher for the urine sample pool.
The bias of the LT-SYS zinc assay was estimated based on two serum based control material samples and resulted in an average bias of 1.3% for the low and 1.5% for the high control level. Arnaud et al. 32 defined minimum quality specifications for the determination of zinc concentrations in human serum or plasma, where <5% bias was defined as optimal relative bias. As such, the bias estimated for the LT-SYS copper assay on a Roche cobas c502 analyzer can well be categorized under the optimal quality specification as defined by Arnaud et al. 32 The LT-SYS zinc assay proved to be linear over the tested measuring range from 1.15 to 34.7 μmol/L (7.51 to 226.9 μg/dL), thus covering the full range from pathological low, to pathological high zinc higher on average. This difference is somewhat compensated by the assay specific reference intervals given by the suppliers, where Wako
gives an approximately 10% higher zinc concentration reference range for its assay compared to LT-SYS zinc assay.
For the LT-SYS Zinc assay the comparison of plasma/serum zinc concentrations showed that plasma samples had an average of 7.3%
higher zinc concentrations than serum samples (LoA: −15.0% to 29.6%; r=.955). This is somewhat surprising since previous studies indicated that serum samples generally have higher zinc concentrations than plasma samples due to the release of zinc from cells during the coagulation process. 16, 20, 21, 33 The measurement of plasma/serum sample pairs, (Figure 3 ) showed a rapid increase of zinc values both in plasma and serum samples. For time intervals above 8 hours zinc concentrations in plasma seem to be higher than in serum, while below 8 hours serum samples have significantly higher zinc values than plasma samples. However, the transport of samples over the pneumatic tube delivery system (PTDS) had the most striking effect on zinc concentrations. Zinc concentrations not only were drastically increased in both plasma and serum samples, but plasma samples on the average had 7.4% significantly higher zinc values than the serum samples. This PTDS induced difference fits perfectly to the 7.3% higher plasma values from the plasma/serum comparison of routine samples, thus explaining the above described discrepancies to previous studies.
The second experimental measuring series tested the effect of time between centrifugation and subsequent analysis (Figure 4 ) including a special blood collecting tube for trace element analysis.
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For both plasma and serum there was no notable increase of zinc concentrations over 96 hours and serum samples had slightly higher zinc F I G U R E 3 Zinc concentrations obtained from plasma and serum tube samples (n=160), centrifuged and analyzed between 0 and 24 hours (h) after blood taking. Shown on the very right and separated by the dashed gray line, are the zinc concentrations obtained from samples sent through the pneumatic tube delivery system (PTDS) before centrifugation and analysis. Plasma (black squares) and serum samples (white circles) are represented as mean±1 SD of 10 samples each F I G U R E 4 Zinc concentrations obtained from plasma, serum, and trace element analysis tubes (n=290) analyzed from 0 up to 96 hours (h) after centrifugation. Zinc concentrations from plasma (black squares), serum (white circles), and trace element analysis tubes (gray triangles) are represented as mean±1 SD of 10 samples each values compared to plasma samples for up to 24 hours after centrifugation. Remarkably, using the trace element tubes did not result in lower zinc concentrations, in fact they even yielded higher zinc concentrations than the normal plasma tubes. The significant increase of zinc concentrations after 8 hours in the trace element tubes can be explained by the lack of a separating gel (serum/plasma tubes had separating gels), resulting in zinc diffusing from the centrifuged blood cells into the supernatant acellular plasma over time.
In sum, measuring zinc is easily influenced by preanalytic factors like time elapsed until separation or the usage of either serum or plasma. Also the mode of transport should be taken into consideration, since the most striking effect on zinc concentrations detected in this study was caused by the PTDS. Even though the usage of special trace element tubes is often recommended, in our study there was no beneficial effect associated with them and the increased costs and effort to use them might thus not always be justified.
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